Moderna, Inc. (MRNA)
| Market Cap | 19.26B +93.5% |
| Revenue (ttm) | 2.23B -30.0% |
| Net Income | -3.19B |
| EPS | -8.16 |
| Shares Out | 396.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,471,300 |
| Open | 51.69 |
| Previous Close | 48.79 |
| Day's Range | 47.78 - 52.00 |
| 52-Week Range | 22.28 - 59.55 |
| Beta | 1.06 |
| Analysts | Hold |
| Price Target | 36.82 (-24.15%) |
| Earnings Date | May 1, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $36.82, which is a decrease of -24.15% from the latest price.
News
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc. (NASDAQ:...
Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial
Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on Wednesday...
Moderna Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by shareholders. No relevant shareholder questions were submitted during the session.
Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
The company states: “Today, Vertex (VRTX) announced that it has decided to discontinue the Phase 1/2 study of the investigational inhaled CFTR mRNA candidate for cystic fibrosis, VX-522. Despite exten...
Moderna price target raised to $45 from $36 at UBS
UBS raised the firm’s price target on Moderna (MRNA) to $45 from $36 and keeps a Neutral rating on the shares. A slew of pipeline updates are coming, and positive
Moderna price target raised to $38 from $35 at RBC Capital
RBC Capital analyst Luca Issi raised the firm’s price target on Moderna (MRNA) to $38 from $35 and keeps a Sector Perform rating on the shares after its better-than-expected Q1
Moderna price target raised to $50 from $35 at Evercore ISI
Evercore ISI raised the firm’s price target on Moderna (MRNA) to $50 from $35 and keeps an In Line rating on the shares. Published first on TheFly – the ultimate
Moderna price target raised to $49 from $43 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Moderna (MRNA) to $49 from $43 and keeps a Neutral rating on the shares after it’s Q1 results. The company’s oncology pipeline
Moderna price target raised to $33 from $30 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $33 from $30 and keeps an Equal Weight rating on the shares. Moderna delivered a Q1 beat on the
Moderna price target raised to $32 from $31 at BofA
BofA analyst Alex Stranahan raised the firm’s price target on Moderna (MRNA) to $32 from $31 and keeps an Underperform rating on the shares after the company reported better-than-expected Q1
Moderna Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth driven by international partnerships and new product approvals, despite a net loss impacted by a major litigation settlement. The company reiterated up to 10% revenue growth for 2026, advanced its late-stage pipeline, and expects pivotal data readouts later this year.
Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.
Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
Moderna reports Q1 EPS ($3.40), consensus ($3.88)
Reports Q1 revenue $389M, consensus $236.36M. “The Moderna (MRNA) team delivered a great start to the year, driving significant revenue growth and substantial cost reductions building on actions taken...
Moderna sees FY26 revenue growth up to 10% vs. FY26
The company said, “Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international. Cost
Moderna Reports Higher Revenue but Posts a Loss
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets.
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0....
CureVac sues Moderna for patent infringement over COVID-19 vaccines
German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to messenger RNA (mRNA) technolog...
Moderna starts late-stage trial of bird flu vaccine in US, UK
Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, marking the first time a pandemic bird flu vaccine made with mRNA technology ha...
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April 2...
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on it...
Moderna wins EU approval for combined flu, COVID shot for older adults
Moderna said on Tuesday the European Commission had granted marketing authorization for a combination vaccine for the prevention of influenza and COVID-19 in adults 50 years of age and ...
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, sub...
Moderna to Present at Upcoming Conferences in May 2026
CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: BofA Securities 2026 Healthcare Confer...
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TP...